FDA Reveals Gender-Based Double Standard in Big Pharma Research

big pharmaQuick poll: Anyone take prescription drugs? Okay, while we count the waving sea of raised arms out there in PR land, the FDA will thank you. Now, for you women out there in that sea, guess what? Big Pharma research is sexist.

No, really. And the FDA just proved it.

A recent study by the U.S. Food and Drug Administration proves that a gender-based double standard exists when it comes to tracking the side-effects of popular prescription drugs.

What was that song about bad medicine again?

The chart below shows us that men and women have very different reactions to certain meds:

men women side effects

Here’s the male side (and the top side-effect has us a little worried):


As the data shows, there are more than 2 million reaction records for women compared to less than 1.3 million for men. Dr. Michael Carome, director of the health research group Public Citizen, said the data doesn’t clarify why more adverse events were reported for women.

“Much of this is voluntary, so there’s likely very significant under reporting. There’s likely many more adverse events occurring than you get from this database.”

(His attorneys would like to thank the FDA for the help on that response.)

More than half of the effects from women were self-reported, which means they are honest and sweet for doing. Men, on the other hand: not so much. Approximately 60% of reported incidences in men were reported by care providers, drug manufacturers, and lawyers.

In short, the research provided does not provide consumers with a full picture due, at least in part, to gender-based differences in the way patients are treated.

Way to go, guys.